AI daily

2026-07-15

OpenAI's GPT-Red Super-Hacker, NVIDIA's Jetson Thor, and Katalyze AI's $10.5M Raise Lead AI News

OpenAI unveils GPT-Red to harden models, NVIDIA launches Jetson Thor for edge AI, and Katalyze AI secures funding for pharma AI agents.

Selected

4

Sources

6

Featured

4

More

0

All reports

AI DAILY BRIEFING

OpenAI has developed GPT-Red, an LLM super-hacker used to simulate cyberattacks and improve model security; GPT-5.6 was trained against it, becoming the most robust release. NVIDIA introduced the T3000 and T2000 Jetson Thor modules for mainstream robotics and edge AI, capable of running foundation models at the edge. Additionally, NVIDIA's DeepStream 9.1 adds multi-camera 3D tracking for video analytics. Katalyze AI raised $10.5M seed funding for its agentic operating system for pharmaceutical companies.

OpenAI's use of GPT-Red to simulate attacks marks a proactive approach to AI safety, potentially setting a new standard for model robustness.

NVIDIA's Jetson Thor modules aim to democratize edge AI and robotics by enabling foundation models on compact, power-efficient hardware.

Katalyze AI's funding underscores growing investor confidence in AI-driven automation for drug development and biopharma operations.

Watch next: Monitor the impact of GPT-Red on future OpenAI releases and industry safety practices; track adoption of Jetson Thor in robotics and edge applications; watch for Katalyze AI's platform deployment in pharma.

Featured

MIT Technology Review AI
3

Meet GPT-Red: An LLM Super-Hacker OpenAI Built to Make Its Models Safer

OpenAI has developed GPT-Red, an LLM designed to act as a super-hacker, to improve the security of its models by simulating cyberattacks. The latest GPT-5.6 was trained against GPT-Red, resulting in its most robust release yet.

SynthePulse InsightRead deep analysis
The AI Insider

Katalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companies

Katalyze AI, which provides an agentic operating system for pharmaceutical companies, has raised $10.5 million in seed funding led by Bonfire Ventures. The platform enables scientists and analysts in biopharma to build AI agent teams. This investment highlights growing interest in AI-driven solutions for drug development.

SynthePulse InsightRead deep analysis